K-ras as a target for cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1756, Issue 2, 2005, Pages 127-144

  Friday, Bret B ^a   Adjei, Alex A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer therapy; Clinical trial; K ras; Oncogene; Ras effector

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 23573; ARRY 142886; CYSMETHYNIL; ENZYME INHIBITOR; EVEROLIMUS; GEMCITABINE; GERANYLTRANSFERASE; ISIS 2503; K RAS PROTEIN; K RAS PROTEIN INHIBITOR; L 778123; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N 116Y H RAS; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RECOMBINANT K RAS PROTEIN; RECOMBINANT PROTEIN; RNA; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; GASTROINTESTINAL TOXICITY; GENE ACTIVATION; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENE STRUCTURE; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, RAS; HUMANS; NEOPLASMS; RAS PROTEINS; RNA INTERFERENCE;

ADENOVIRIDAE;

EID: 28844509531     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2005.08.001     Document Type: Review

References (194)

1. C.A. Ellis, and G. Clark The importance of being K-Ras Cell. Signal. 12 2000 425 434
2. A.A. Adjei Ras signaling pathway proteins as therapeutic targets Curr. Pharm. Des. 7 2001 1581 1594
3. A.A. Adjei Blocking oncogenic Ras signaling for cancer therapy J. Natl. Cancer. Inst. 93 2001 1062 1074
4. M. Barbacid ras genes Annu. Rev. Biochem. 56 1987 779 827
5. D.R. Lowy, and B.M. Willumsen Function and regulation of ras Annu. Rev. Biochem. 62 1993 851 891
6. A. Ehrhardt, G.R.A. Ehrhardt, X. Guo, and J.W. Schrader Ras and relatives-Job sharing and networking keep an old family together Exp. Hematol. 30 2002 1089 1106
7. E.H. Chang, M.A. Gonda, R.W. Ellis, E.M. Scolnick, and D.R. Lowy Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses Proc. Natl. Acad. Sci. U. S. A. 79 1982 4848 4852
8. K. Shimizu, M. Goldfarb, M. Perucho, and M. Wigler Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line Proc. Natl. Acad. Sci. U. S. A. 80 1983 383 387
9. A. Hall, C.J. Marshall, N.K. Spurr, and R.A. Weiss Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1 Nature 303 1983 396 400
10. D.C. Dykes, P. Brandt-Rauf, S.M. Luster, F.K. Friedman, and M.R. Pincus Activated conformations of the ras-gene-encoded p21 protein: II. Comparison of the computed and high-resolution X-ray crystallographic structures of Gly-12 p21 J. Biomol. Struct. Dyn. 10 1993 905 918
11. D.C. Dykes, P. Brandt-Rauf, S.M. Luster, D. Chung, F.K. Friedman, and M.R. Pincus Activated conformations of the ras-gene-encoded p21 protein: I. An energy-refined structure for the normal p21 protein complexed with GDP J. Biomol. Struct. Dyn. 9 1992 1025 1044
12. E.F. Pai, U. Krengel, G.A. Petsko, R.S. Goody, W. Kabsch, and A. Wittinghofer Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis EMBO J. 9 1990 2351 2359
13. E.F. Pai, W. Kabsch, U. Krengel, K.C. Holmes, J. John, and A. Wittinghofer Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation Nature 341 1989 209 214
14. P.A. Boriack-Sjodin, S.M. Margarit, D. Bar-Sagi, and J. Kuriyan The structural basis of the activation of Ras by Sos Nature 394 1998 337 343
15. S.M. Margarit, H. Sondermann, B.E. Hall, B. Nagar, A. Hoelz, M. Pirruccello, D. Bar-Sagi, and J. Kuriyan Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS Cell 112 2003 685 695
16. N. Imamura, A. Kuramoto, H. Ishihara, and S. Shimizu Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia Am. J. Hematol. 43 1993 151 153
17. T. Hongyo, G.S. Buzard, D. Palli, C.M. Weghorst, A. Amorosi, M. Galli, N.E. Caporaso, J.F. Fraumeni Jr., and J.M. Rice Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy Cancer Res. 55 1995 2665 2672
18. Y. Suzuki, M. Orita, M. Shiraishi, K. Hayashi, and T. Sekiya Detection of Ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products Oncogene 5 1990 1037 1043
19. K. Tsukuda, M. Tanino, H. Soga, N. Shimizu, and K. Shimizu A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma Biochem. Biophys. Res. Commun. 278 2000 653 658
20. I.M. Ghobrial, and A.A. Adjei Inhibitors of the ras oncogene as therapeutic targets Hematol. Oncol. Clin. N. Am. 16 2002 1065 1088
21. A.A. Adjei Farnesyltransferase inhibitors Cancer Chemother. Biol. Response Modif. 19 2001 149 164
22. K.N. Cho, and K.I. Lee Chemistry and biology of Ras farnesyltransferase Arch. Pharm. Res. 25 2002 759 769
23. M.D. Schaber, M.B. O'Hara, V.M. Garsky, S.C. Mosser, J.D. Bergstrom, S.L. Moores, M.S. Marshall, P.A. Friedman, R.A. Dixon, and J.B. Gibbs Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase J. Biol. Chem. 265 1990 14701 14704
24. S.L. Moores, M.D. Schaber, S.D. Mosser, E. Rands, M.B. O'Hara, V.M. Garsky, M.S. Marshall, D.L. Pompliano, and J.B. Gibbs Sequence dependence of protein isoprenylation J. Biol. Chem. 266 1991 14603 14610
25. D.B. Whyte, P. Kirschmeier, T.N. Hockenberry, I. Nunez-Oliva, L. James, J.J. Catino, W.R. Bishop, and J.K. Pai K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J. Biol. Chem. 272 1997 14459 14464
26. M.C. Seabra, J.L. Goldstein, T.C. Sudhof, and M.S. Brown Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys J. Biol. Chem. 267 1992 14497 14503
27. C.C. Farnsworth, M.C. Seabra, L.H. Ericsson, M.H. Gelb, and J.A. Glomset Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A Proc. Natl. Acad. Sci. U. S. A. 91 1994 11963 11967
28. C.E. Trueblood, V.L. Boyartchuk, E.A. Picologlou, D. Rozema, C.D. Poulter, and J. Rine The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities Mol. Cell. Biol. 20 2000 4381 4392
29. S. Clarke Protein isoprenylation and methylation at carboxyl-terminal cysteine residues Annu. Rev. Biochem. 61 1992 355 386
30. M.D. Resh Membrane targeting of lipid modified signal transduction proteins Sub-cell. Biochem. 37 2004 217 232
31. J.H. Jackson, J.W. Li, J.E. Buss, C.J. Der, and C.G. Cochrane Polylysine domain of K-ras 4B protein is crucial for malignant transformation Proc. Natl. Acad. Sci. U. S. A. 91 1994 12730 12734
32. C. Liebmann Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity Cell. Signal. 13 2001 777 785
33. J. Avruch, A. Khokhlatchev, J.M. Kyriakis, Z. Luo, G. Tzivion, D. Vavvas, and X.F. Zhang Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade Recent Prog. Horm. Res. 56 2001 127 155
34. Y. Li, M.I. Gonzalez, J.L. Meinkoth, J. Field, M.G. Kazanietz, and G.I. Tennekoon Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells J. Biol. Chem. 278 2003 9585 9591
35. K. Kinbara, L.E. Goldfinger, M. Hansen, F.L. Chou, and M.H. Ginsberg Ras GTPases: integrins' friends or foes? Nat. Rev., Mol. Cell Biol. 4 2003 767 776
36. L.V. Parise, J. Lee, and R.L. Juliano New aspects of integrin signaling in cancer Semin. Cancer Biol. 10 2000 407 414
37. D.A. Cantrell GTPases and T cell activation Immunol. Rev. 192 2003 122 130
38. S.W. Henning, and D.A. Cantrell GTPases in antigen receptor signalling Curr. Opin. Immunol. 10 1998 322 339
39. C.H. Heldin Dimerization of cell surface receptors in signal transduction Cell 80 1995 213 223
40. M.A. Lemmon, and J. Schlessinger Regulation of signal transduction and signal diversity by receptor oligomerization Trends Biochem. Sci. 19 1994 459 463
41. F.U. Weiss, H. Daub, and A. Ullrich Novel mechanisms of RTK signal generation Curr. Opin. Genet. Dev. 7 1997 80 86
42. J. Schlessinger Cell Signaling by receptor tyrosine kinases Cell 103 2000 211 225
43. L.A. Quilliam, S.Y. Huff, K.M. Rabun, W. Wei, W. Park, D. Broek, and C.J. Der Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity Proc. Natl. Acad. Sci. U. S. A. 91 1994 8512 8516
44. H. Sondermann, S.M. Soisson, S. Boykevisch, S.S. Yang, D. Bar-Sagi, and J. Kuriyan Structural analysis of autoinhibition in the Ras activator Son of sevenless Cell 119 2004 393 405
45. A. Bernards, and J. Settleman GAP control: regulating the regulators of small GTPases Trends Cell Biol. 14 2004 377 385
46. R.M. Reynolds, G.G. Browning, I. Nawroz, and I.W. Campbell Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1 Lancet 361 2003 1552 1554
47. R. Finney, and D. Herrera Ras-Raf complexes: analyses of complexes formed in vivo Methods Enzymol. 255 1995 310 323
48. R. Marais, Y. Light, H.F. Paterson, and C.J. Marshall Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation EMBO J. 14 1995 3136 3145
49. L.M. Johnson, K.M. James, M.D. Chamberlain, and D.H. Anderson Identification of key residues in the A-Raf kinase important for phosphoinositide lipid binding specificity Biochemistry 44 2005 3432 3440
50. S. Ghosh, S. Moore, R.M. Bell, and M. Dush Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos J. Biol. Chem. 278 2003 45690 45696
51. J.K. Voice, R.L. Klemke, A. Le, and J.H. Jackson Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility J. Biol. Chem. 274 1999 17164 17170
52. T. Heinicke, G. Radziwill, M. Nawrath, C. Rommel, J. Pavlovic, and K. Moelling Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation Cancer Gene Ther. 7 2000 697 706
53. T.I. Bonner, S.B. Kerby, P. Sutrave, M.A. Gunnell, G. Mark, and U.R. Rapp Structure and biological activity of human homologs of the raf/mil oncogene Mol. Cell. Biol. 5 1985 1400 1407
54. S. Cowley, H. Paterson, P. Kemp, and C.J. Marshall Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells Cell 77 1994 841 852
55. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
56. M. Maekawa, E. Nishida, and T. Tanoue Identification of the Anti-proliferative protein Tob as a MAPK substrate J. Biol. Chem. 277 2002 37783 37787
57. P.P. Roux, B.A. Ballif, R. Anjum, S.P. Gygi, and J. Blenis Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase Proc. Natl. Acad. Sci. U. S. A. 101 2004 13489 13494
58. B.J. Ledwith, S. Manam, A.R. Kraynak, W.W. Nichols, and M.O. Bradley Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene Mol. Cell. Biol. 10 1990 1545 1555
59. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker, and M.D. Waterfield Synthesis and function of 3-phosphorylated inositol lipids Annu. Rev. Biochem. 70 2001 535 602
60. P. Rodriguez-Viciana, P.H. Warne, B. Vanhaesebroeck, M.D. Waterfield, and J. Downward Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation EMBO J. 15 1996 2442 2451
61. P. Rodriguez-Viciana, P.H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, M.J. Fry, M.D. Waterfield, and J. Downward Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature 370 1994 527 532
62. P. Rodriguez-Viciana, P.H. Warne, A. Khwaja, B.M. Marte, D. Pappin, P. Das, M.D. Waterfield, A. Ridley, and J. Downward Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras Cell 89 1997 457 467
63. G. Song, G. Ouyang, and S. Bao The activation of Akt/PKB signaling pathway and cell survival J. Cell. Mol. Med. 9 2005 59 71
64. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res. 61 2001 3986 3997
65. M. Wislez, M.L. Spencer, J.G. Izzo, D.M. Juroske, K. Balhara, D.D. Cody, R.E. Price, W.N. Hittelman, I.I. Wistuba, and J.M. Kurie Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras Cancer Res. 65 2005 3226 3235
66. P. Crespo, K.E. Schuebel, A.A. Ostrom, J.S. Gutkind, and X.R. Bustelo Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product Nature 385 1997 169 172
67. Y. Takai, T. Sasaki, and T. Matozaki Small GTP-binding proteins Physiol Rev. 81 2001 153 208
68. J.W. Huang, C.L. Chen, and N.N. Chuang Trap RACK1 with Ras to mobilize Src signaling at syndecan-2/p120-GAP upon transformation with oncogenic ras Biochem. Biophys. Res. Commun. 330 2005 1087 1094
69. J.W. Huang, C.L. Chen, and N.N. Chuang P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras Biochem. Biophys. Res. Commun. 329 2005 855 862
70. T. Corral, M. Jimenez, I. Hernandez-Munoz, I. Perez de Castro, and A. Pellicer NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity J. Cell. Physiol. 197 2003 214 224
71. T.K. Schlesinger, G.R. Fanger, T. Yujiri, and G.L. Johnson The TAO of MEKK Front. Biosci. 3 1998 D1181 D1186
72. M. Karandikar, S. Xu, and M.H. Cobb MEKK1 binds raf-1 and the ERK2 cascade components J. Biol. Chem. 275 2000 40120 40127
73. S. Boldt, U.H. Weidle, and W. Kolch The kinase domain of MEKK1 induces apoptosis by dysregulation of MAP kinase pathways Exp. Cell Res. 283 2003 80 90
74. M. Russell, C.A. Lange-Carter, and G.L. Johnson Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1) J. Biol. Chem. 270 1995 11757 11760
75. D. Bian, S. Su, C. Mahanivong, R.K. Cheng, Q. Han, Z.K. Pan, P. Sun, and S. Huang Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway Cancer Res. 64 2004 4209 4217
76. K.M. de Bruyn, J. de Rooij, R.M. Wolthuis, H. Rehmann, J. Wesenbeek, R.H. Cool, A.H. Wittinghofer, and J.L. Bos RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral J. Biol. Chem. 275 2000 29761 29766
77. D.R. D'Adamo, S. Novick, J.M. Kahn, P. Leonardi, and A. Pellicer rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral Oncogene 14 1997 1295 1305
78. A. Gonzalez-Garcia, C.A. Pritchard, H.F. Paterson, G. Mavria, G. Stamp, and C.J. Marshall RalGDS is required for tumor formation in a model of skin carcinogenesis Cancer Cell 7 2005 219 226
79. T. Urano, R. Emkey, and L.A. Feig Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation EMBO J. 15 1996 810 816
80. S.T. Dergham, M.C. Dugan, R. Kucway, W. Du, D.S. Kamarauskiene, V.K. Vaitkevicius, J.D. Crissman, and F.H. Sarkar Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma Int. J. Pancreatol. 21 1997 127 143
81. J.Y. Wang, S.T. Lian, Y.F. Chen, Y.C. Yang, L.T. Chen, K.T. Lee, T.J. Huang, and S.R. Lin Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients Cancer Lett. 180 2002 153 158
82. D. Shibata, C. Almoguera, K. Forrester, J. Dunitz, S.E. Martin, M.M. Cosgrove, M. Perucho, and N. Arnheim Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas Cancer Res. 50 1990 1279 1283
83. J.S. Goydos, B. Mann, H.J. Kim, E.M. Gabriel, J. Alsina, F.J. Germino, W. Shih, and D.H. Gorski Detection of B-RAF and N-RAS mutations in human melanoma J. Am. Coll. Surg. 200 2005 362 370
84. J. Reifenberger, C.B. Knobbe, A.A. Sterzinger, B. Blaschke, K.W. Schulte, T. Ruzicka, and G. Reifenberger Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas Int. J. Cancer 109 2004 377 384
85. G.W. Reuther, and C.J. Der The Ras branch of small GTPases: Ras family members don't fall far from the tree Curr. Opin. Cell Biol. 12 2000 157 165
86. S.M. Sebti, and A.A. Adjei Farnesyltransferase inhibitors Semin. Oncol. 31 2004 28 39
87. C. Galiana, J.C. Lozano, B. Bancel, H. Nakazawa, and H. Yamasaki High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus Mol. Carcinog. 14 1995 286 293
88. W.B. Coleman, D.B. Throneburg, J.W. Grisham, and G.J. Smith Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines Carcinogenesis 15 1994 1005 1012
89. F.C. von Lintig, A.D. Dreilinger, N.M. Varki, A.M. Wallace, D.E. Casteel, and G.R. Boss Ras activation in human breast cancer Breast Cancer Res. Treat. 62 2000 51 62
90. C.-Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, C.-L. Ho, R.J. Kurman, T.-L. Wang, and I.-M. Shih Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin. Cancer Res. 10 2004 6432 6436
91. J. Tabernero, R. Salazar, E. Casado, E. Martinelli, P. Gomez, and J. Baselga Targeted therapy in advanced colon cancer: the role of new therapies Ann. Oncol. 15 Suppl. 4 2004 iv55 iv62
92. Y. Yarden, J. Baselga, and D. Miles Molecular approach to breast cancer treatment Semin. Oncol. 31 2004 6 13
93. F. Alexander-Sefre, H.B. Salvesen, A. Ryan, N. Singh, L.A. Akslen, N. MacDonald, G. Wilbanks, and I.J. Jacobs Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis Gynecol. Oncol. 91 2003 218 225
94. C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, M. Dusart, A. Haller, P. Lothaire, A.P. Meert, S. Noel, J.J. Lafitte, and J.P. Sculier The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br. J. Cancer 92 2005 131 139
95. G. Garcia-Rostan, H. Zhao, R.L. Camp, M. Pollan, A. Herrero, J. Pardo, R. Wu, M.L. Carcangiu, J. Costa, and G. Tallini ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer J. Clin. Oncol. 21 2003 3226 3235
96. W.S. Samowitz, K. Curtin, D. Schaffer, M. Robertson, M. Leppert, and M.L. Slattery Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study Cancer Epidemiol. Biomarkers Prev. 9 2000 1193 1197
97. H.J. Andreyev, A.R. Norman, D. Cunningham, J. Oates, B.R. Dix, B.J. Iacopetta, J. Young, T. Walsh, R. Ward, N. Hawkins, M. Beranek, P. Jandik, R. Benamouzig, E. Jullian, P. Laurent-Puig, S. Olschwang, O. Muller, I. Hoffmann, H.M. Rabes, C. Zietz, C. Troungos, C. Valavanis, S.T. Yuen, J.W. Ho, C.T. Croke, D.P. O'Donoghue, W. Giaretti, A. Rapallo, A. Russo, V. Bazan, M. Tanaka, K. Omura, T. Azuma, T. Ohkusa, T. Fujimori, Y. Ono, M. Pauly, C. Faber, R. Glaesener, A.F. de Goeij, J.W. Arends, S.N. Andersen, T. Lovig, J. Breivik, G. Gaudernack, O.P. Clausen, P.D. De Angelis, G.I. Meling, T.O. Rognum, R. Smith, H.S. Goh, A. Font, R. Rosell, X.F. Sun, H. Zhang, J. Benhattar, L. Losi, J.Q. Lee, S.T. Wang, P.A. Clarke, S. Bell, P. Quirke, V.J. Bubb, J. Piris, N.R. Cruickshank, D. Morton, J.C. Fox, F. Al-Mulla, N. Lees, C.N. Hall, D. Snary, K. Wilkinson, D. Dillon, J. Costa, V.E. Pricolo, S.D. Finkelstein, J.S. Thebo, A.J. Senagore, S.A. Halter, S. Wadler, S. Malik, K. Krtolica, and N. Urosevic Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br. J. Cancer 85 2001 692 696
98. P. Laurent-Puig, S. Olschwang, O. Delattre, Y. Remvikos, B. Asselain, T. Melot, P. Validire, M. Muleris, J. Girodet, and R.J. Salmon Survival and acquired genetic alterations in colorectal cancer Gastroenterology 102 1992 1136 1141
99. J. Boonstra, P. Rijken, B. Humbel, F. Cremers, A. Verkleij, and P. van Bergen en Henegouwen The epidermal growth factor Cell Biol. Int. 19 1995 413 430
100. D.W. Stacey Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells Curr. Opin. Cell Biol. 15 2003 158 163
101. J. Downward PI 3-kinase, Akt and cell survival Semin. Cell Dev. Biol. 15 2004 177 182
102. L.A. Cary, D.C. Han, and J.L. Guan Integrin-mediated signal transduction pathways Histol. Histopathol. 14 1999 1001 1009
103. O. Kranenburg, M.F. Gebbink, and E.E. Voest Stimulation of angiogenesis by Ras proteins Biochim. Biophys. Acta 1654 2004 23 37
104. C.J. Der, T.G. Krontiris, and G.M. Cooper Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses Proc. Natl. Acad. Sci. U. S. A. 79 1982 3637 3640
105. C. Shih, L.C. Padhy, M. Murray, and R.A. Weinberg Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts Nature 290 1981 261 264
106. C. Caulin, T. Nguyen, M.A. Longley, Z. Zhou, X.J. Wang, and D.R. Roop Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity Cancer Res. 64 2004 5054 5058
107. L. Vitale-Cross, P. Amornphimoltham, G. Fisher, A.A. Molinolo, and J.S. Gutkind Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis Cancer Res. 64 2004 8804 8807
108. D.A. Tuveson, A.T. Shaw, N.A. Willis, D.P. Silver, E.L. Jackson, S. Chang, K.L. Mercer, R. Grochow, H. Hock, D. Crowley, S.R. Hingorani, T. Zaks, C. King, M.A. Jacobetz, L. Wang, R.T. Bronson, S.H. Orkin, R.A. DePinho, and T. Jacks Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects Cancer Cell 5 2004 375 387
109. I.T. Chan, J.L. Kutok, I.R. Williams, S. Cohen, L. Kelly, H. Shigematsu, L. Johnson, K. Akashi, D.A. Tuveson, T. Jacks, and D.G. Gilliland Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease J. Clin. Invest. 113 2004 528 538
110. R.D. Odze, T. Brien, C.A. Brown, C.J. Hartman, A. Wellman, and F. Fogt Molecular alterations in chronic ulcerative colitis-associated and sporadic hyperplastic polyps: a comparative analysis Am. J. Gastroenterol. 97 2002 1235 1242
111. K. Otori, Y. Oda, K. Sugiyama, T. Hasebe, K. Mukai, T. Fujii, H. Tajiri, S. Yoshida, S. Fukushima, and H. Esumi High frequency of K-ras mutations in human colorectal hyperplastic polyps Gut 40 1997 660 663
112. M. Arvanitakis, J.L. Van Laethem, J. Parma, V. De Maertelaer, M. Delhaye, and J. Deviere Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation Endoscopy 36 2004 535 542
113. J.M. Spencer, S.M. Kahn, W. Jiang, V.A. DeLeo, and I.B. Weinstein Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas Arch. Dermatol. 131 1995 796 800
114. Y. Ogiso, L. Gutierrez, L.S. Wrathall, Y.Y. Lu, D.G. Blair, D.J. Clanton, Y.W. Hwang, and T.Y. Shih trans-Dominant suppressor mutations of the H-ras oncogene Cell Growth Differ. 1 1990 217 224
115. D.J. Clanton, S. Hattori, and T.Y. Shih Mutations of the ras gene product p21 that abolish guanine nucleotide binding Proc. Natl. Acad. Sci. U. S. A. 83 1986 5076 5080
116. N. Senmaru, T. Shichinohe, M. Takeuchi, M. Miyamoto, A. Sazawa, Y. Ogiso, T. Takahashi, S. Okushiba, M. Takimoto, H. Kato, and N. Kuzumaki Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y Int. J. Cancer 78 1998 366 371
117. T. Shichinohe, N. Senmaru, K. Furuuchi, Y. Ogiso, H. Ishikura, T. Yoshiki, T. Takahashi, H. Kato, and N. Kuzumaki Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y J. Surg. Res. 66 1996 125 130
118. Y. Ogiso, N. Sakai, H. Watari, T. Yokoyama, and N. Kuzumaki Suppression of various human tumor cell lines by a dominant negative H-ras mutant Gene Ther. 1 1994 403 407
119. M. Takeuchi, T. Shichinohe, N. Senmaru, M. Miyamoto, H. Fujita, M. Takimoto, S. Kondo, H. Katoh, and N. Kuzumaki The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice Gene Ther. 7 2000 518 526
120. P. Bossu, M. Vanoni, V. Wanke, M.P. Cesaroni, F. Tropea, G. Melillo, C. Asti, S. Porzio, P. Ruggiero, V. Di Cioccio, G. Maurizi, A. Ciabini, and L. Alberghina A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts Oncogene 19 2000 2147 2154
121. S. Shirasawa, M. Furuse, N. Yokoyama, and T. Sasazuki Altered growth of human colon cancer cell lines disrupted at activated Ki-ras Science 260 1993 85 88
122. A.M. Duursma, and R. Agami Ras interference as cancer therapy Semin. Cancer Biol. 13 2003 267 273
123. G.D. Gray, O.M. Hernandez, D. Hebel, M. Root, J.M. Pow-Sang, and E. Wickstrom Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice Cancer Res. 53 1993 577 580
124. Y. Zhang, T. Mukhopadhyay, L.A. Donehower, R.N. Georges, and J.A. Roth Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype Hum. Gene Ther. 4 1993 451 460
125. R.N. Georges, T. Mukhopadhyay, Y. Zhang, N. Yen, and J.A. Roth Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct Cancer Res. 53 1993 1743 1746
126. Y. Miura, S. Ohnami, K. Yoshida, M. Ohashi, M. Nakano, M. Fukuhara, K. Yanagi, A. Matsushita, E. Uchida, M. Asaka, T. Yoshida, and K. Aoki Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity Cancer Lett. 218 2005 53 62
127. G. Chen, S. Oh, B.P. Monia, and D.W. Stacey Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts J. Biol. Chem. 271 1996 28259 28265
128. J.T. Holmlund, B.P. Monia, T.J. Kwoh, and F.A. Dorr Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development Curr. Opin. Mol. Ther. 1 1999 372 385
129. C.C. Cunningham, J.T. Holmlund, R.S. Geary, T.J. Kwoh, A. Dorr, J.F. Johnston, B. Monia, and J. Nemunaitis A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma Cancer 92 2001 1265 1271
130. A.A. Adjei, G.K. Dy, C. Erlichman, J.M. Reid, J.A. Sloan, H.C. Pitot, S.R. Alberts, R.M. Goldberg, L.J. Hanson, P.J. Atherton, T. Watanabe, R.S. Geary, J. Holmlund, and F.A. Dorr A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer Clin. Cancer Res. 9 2003 115 123
131. S.R. Alberts, M. Schroeder, C. Erlichman, P.D. Steen, N.R. Foster, D.F. Moore Jr., K.M. Rowland Jr., S. Nair, L.K. Tschetter, and T.R. Fitch Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial J. Clin. Oncol. 22 2004 4944 4950
132. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
133. G.J. Hannon RNA interference Nature 418 2002 244 251
134. T.R. Brummelkamp, R. Bernards, and R. Agami Stable suppression of tumorigenicity by virus-mediated RNA interference Cancer Cell 2 2002 243 247
135. K. Kato, A.D. Cox, M.M. Hisaka, S.M. Graham, J.E. Buss, and C.J. Der Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity Proc. Natl. Acad. Sci. U. S. A. 89 1992 6403 6407
136. A.A. Adjei Farnesyltransferase inhibitors Cancer Chemother. Biol. Response Modif. 21 2003 127 144
137. P. Haluska, G.K. Dy, and A.A. Adjei Farnesyl transferase inhibitors as anticancer agents Eur. J. Cancer 38 2002 1685 1700
138. S.M. Sebti Blocked pathways: FTIs shut down oncogene signals Oncologist 8 Suppl. 3 2003 30 38
139. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, A. Devine, W. Wouters, and C. Bowden Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res. 61 2001 131 137
140. J. Sun, Y. Qian, A.D. Hamilton, and S.M. Sebti Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion Cancer Res. 55 1995 4243 4247
141. J.E. Karp, J.E. Lancet, S.H. Kaufmann, D.W. End, J.J. Wright, K. Bol, I. Horak, M.L. Tidwell, J. Liesveld, T.J. Kottke, D. Ange, L. Buddharaju, I. Gojo, W.E. Highsmith, R.T. Belly, R.J. Hohl, M.E. Rybak, A. Thibault, and J. Rosenblatt Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood 97 2001 3361 3369
142. S.R. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J.J. Perez-Ruixo, P. Palmer, and A. Howes Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer J. Clin. Oncol. 21 2003 2492 2499
143. S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, A. Illes, R. Belly, J.J. Perez-Ruixo, Y.C. Park, and P.A. Palmer Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer J. Clin. Oncol. 22 2004 3950 3957
144. E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, A. Szawlowski, P. Schoffski, S. Post, C. Verslype, H. Neumann, H. Safran, Y. Humblet, J. Perez Ruixo, Y. Ma, and D. Von Hoff Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J. Clin. Oncol. 22 2004 1430 1438
145. G.C. Prendergast, J.P. Davide, S.J. deSolms, E.A. Giuliani, S.L. Graham, J.B. Gibbs, A. Oliff, and N.E. Kohl Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton Mol. Cell. Biol. 14 1994 4193 4202
146. L. Sepp-Lorenzino, Z. Ma, E. Rands, N.E. Kohl, J.B. Gibbs, A. Oliff, and N. Rosen A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res. 55 1995 5302 5309
147. J. Sun, Y. Qian, A.D. Hamilton, and S.M. Sebti Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts Oncogene 16 1998 1467 1473
148. R.B. Lobell, D. Liu, C.A. Buser, J.P. Davide, E. DePuy, K. Hamilton, K.S. Koblan, Y. Lee, S. Mosser, S.L. Motzel, J.L. Abbruzzese, C.S. Fuchs, E.K. Rowinsky, E.H. Rubin, S. Sharma, P.J. Deutsch, K.E. Mazina, B.W. Morrison, L. Wildonger, S.L. Yao, and N.E. Kohl Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl:protein transferase type-I Mol. Cancer Ther. 1 2002 747 758
149. C.D. Britten, E.K. Rowinsky, S. Soignet, A. Patnaik, S.L. Yao, P. Deutsch, Y. Lee, R.B. Lobell, K.E. Mazina, H. McCreery, S. Pezzuli, and D. Spriggs A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies Clin. Cancer Res. 7 2001 3894 3903
150. M.O. Bergo, P. Ambroziak, C. Gregory, A. George, J.C. Otto, E. Kim, H. Nagase, P.J. Casey, A. Balmain, and S.G. Young Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation Mol. Cell. Biol. 22 2002 171 181
151. E. Kim, P. Ambroziak, J.C. Otto, B. Taylor, M. Ashby, K. Shannon, P.J. Casey, and S.G. Young Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells J. Biol. Chem. 274 1999 8383 8390
152. A.M. Winter-Vann, R.A. Baron, W. Wong, J. dela Cruz, J.D. York, D.M. Gooden, M.O. Bergo, S.G. Young, E.J. Toone, and P.J. Casey A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells Proc. Natl. Acad. Sci. U. S. A. 102 2005 4336 4341
153. M.K. Gjertsen, and G. Gaudernack Mutated Ras peptides as vaccines in immunotherapy of cancer Vox Sang. 74 Suppl. 2 1998 489 495
154. B. Fossum, A.C. Olsen, E. Thorsby, and G. Gaudernack CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation Cancer Immunol. Immunother. 40 1995 165 172
155. M.K. Gjertsen, T. Buanes, A.R. Rosseland, A. Bakka, I. Gladhaug, O. Soreide, J.A. Eriksen, M. Moller, I. Baksaas, R.A. Lothe, I. Saeterdal, and G. Gaudernack Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma Int. J. Cancer 92 2001 441 450
156. S.N. Khleif, S.I. Abrams, J.M. Hamilton, E. Bergmann-Leitner, A. Chen, A. Bastian, S. Bernstein, Y. Chung, C.J. Allegra, and J. Schlom A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors J. Immunother. 22 1999 155 165
157. A.C. Stubbs, K.S. Martin, C. Coeshott, S.V. Skaates, D.R. Kuritzkes, D. Bellgrau, A. Franzusoff, R.C. Duke, and C.C. Wilson Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity Nat. Med. 7 2001 625 629
158. Y. Lu, D. Bellgrau, L.D. Dwyer-Nield, A.M. Malkinson, R.C. Duke, T.C. Rodell, and A. Franzusoff Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy Cancer Res. 64 2004 5084 5088
159. E.O. Nuzum, A.M. Malkinson, and D.G. Beer Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas Mol. Carcinog. 3 1990 287 295
160. M.R. Pincus Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins Front. Biosci. 9 2004 3486 3509
161. S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol. Cancer Ther. 4 2005 677 685
162. M. Heim, M. Sharifi, R.A. Hilger, M.E. Scheulen, S. Seeber, and D. Strumberg Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006 Int. J. Clin. Pharmacol. Ther. 41 2003 616 617
163. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and P.A. Trail BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109
164. D. Strumberg, H. Richly, R.A. Hilger, N. Schleucher, S. Korfee, M. Tewes, M. Faghih, E. Brendel, D. Voliotis, C.G. Haase, B. Schwartz, A. Awada, R. Voigtmann, M.E. Scheulen, and S. Seeber Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J. Clin. Oncol. 23 2005 965 972
165. M.J. Ratain, T. Eisen, W.M. Stadler, K.T. Flaherty, M. Gore, A. Desai, A. Patnaik, H.Q. Xiong, B. Schwartz, and P. O'Dwyer Final findings from a I.I. Phase, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) 2005 ASCO Annual Meeting Proceedings Journal of Clinical Oncology vol. 23 2005 4544
166. B. Escudier, C. Szczylik, T. Eisen, W.M. Stadler, B. Schwartz, M. Shan, and R.M. Bukowski Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) 2005 ASCO Annual Meeting Proceedings Journal of Clinical Oncology vol. 23 2005 LBA4510
167. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R.C. Gowan, H. Tecle, S.D. Barrett, A. Bridges, S. Przybranowski, W.R. Leopold, and A.R. Saltiel Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat. Med. 5 1999 810 816
168. P.M. LoRusso, A.A. Adjei, M.B. Meyer, A. Wozniak, S.M. Gadgeel, L.J. Hanson, J.M. Reid, D.Y. Mitchell, L.M. Bruzek, J.S. Leopold, R. Herrera, K. Van Becelaere, T. Carlson, C. Packard, S.W. Gulyas, and C. Erlichman Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) 2002 ASCO Annual Meeting Proceedings Journal of Clinical Oncology vol. 21 2002 81a
169. J. Rinehart, A.A. Adjei, P.M. Lorusso, D. Waterhouse, J.R. Hecht, R.B. Natale, O. Hamid, M. Varterasian, P. Asbury, E.P. Kaldjian, S. Gulyas, D.Y. Mitchell, R. Herrera, J.S. Sebolt-Leopold, and M.B. Meyer Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J. Clin. Oncol. 22 2004 4456 4462
170. J.S. Sebolt-Leopold, and R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat. Rev., Cancer 4 2004 937 947
171. J. Lyssikatos, T. Yeh, E. Wallace, V. Marsh, B. Bernat, S. Gross, R. Evans, H. Colwell, J. Parry, S. Baker, J. Ballard, T. Morales, D. Smith, B. Brandhuber, and J. Winkler ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectively Annu. Meet. Am. Assoc. Cancer Res., Proc. 42 2004 a3888
172. E. Wallace, T. Yeh, J. Lyssikatos, J. Winkler, P. lee, A. Marlow, B. Hurley, V. Marsh, B. Bernat, R. Evans, H. Colwell, J. Ballard, T. Morales, D. Smith, B. Brandhuber, S. Gross, G. Poch, K. Litweiler, G. Hingorani, J. Otten, F. Sullivan, J. Blake, T. Pheneger, M. Goyette, and K. Koch Preclinical development of ARRY-142886, a potent and selective MEK inhibitor Annu. Meet. Am. Assoc. Cancer Res., Proc. 45 2004 a3891
173. S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Oncol. 16 2005 525 537
174. J. Shao, B.M. Evers, and H. Sheng Roles of phosphatidylinositol 3′-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells Cancer Res. 64 2004 229 235
175. C. Agbunag, and D. Bar-Sagi Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells Cancer Res. 64 2004 5659 5663
176. L. Wu, D.C. Birle, and I.F. Tannock Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Res. 65 2005 2825 2831
177. L.A. DeGraffenried, L. Fulcher, W.E. Friedrichs, V. Grunwald, R.B. Ray, and M. Hidalgo Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway Ann. Oncol. 15 2004 1510 1516
178. P. Frost, F. Moatamed, B. Hoang, Y. Shi, J. Gera, H. Yan, J. Gibbons, and A. Lichtenstein In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model Blood 104 2004 4181 4187
179. E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, C. Leister, J. Korth-Bradley, A. Hanauske, and J.P. Armand Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J. Clin. Oncol. 22 2004 2336 2347
180. K.J. Pandya, D.E. Levy, M. Hidalgo, R.B. Cohen, M.W. Lee, J.H. Schiller, and D.H. Johnson A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report J. Clin. Oncol. (Meet. Abstr.) 23 2005 7005
181. E. Galanis, J.C. Buckner, M.J. Maurer, M. Hidalgo, J.I. Kreisberg, J. Peralba, R.B. Jenkins, and D.J. Walsh N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): updated results and correlative laboratory analysis J. Clin. Oncol. (Meet. Abstr.) 23 2005 1505
182. T.E. Witzig, S.M. Ansell, S.M. Geyer, P.J. Kurtin, K.M. Rowland, P.J. Flynn, R.F. Morton, S.R. Dakhil, H.M. Gross, M.J. Maurer, and S.H. Kaufmann Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: a phase II trial in the North Central Cancer Treatment Group J. Clin. Oncol. (Meet. Abstr.) 23 2005 6504
183. J.L. Bos, E.R. Fearon, S.R. Hamilton, M. Verlaan-de Vries, J.H. van Boom, A.J. van der Eb, and B. Vogelstein Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297
184. U. Kressner, J. Bjorheim, S. Westring, S.S. Wahlberg, L. Pahlman, B. Glimelius, G. Lindmark, A. Lindblom, and A.L. Borresen-Dale Ki-ras mutations and prognosis in colorectal cancer Eur. J. Cancer 34 1998 518 521
185. P. Moerkerk, J. Arends, M. van Driel, A. de Bruine, A. de Goeij, and J. ten Kate Type and number of Ki-ras point mutations relate to stage of human colorectal cancer Cancer Res. 54 1994 3376 3378
186. M.L. Gemignani, A.C. Schlaerth, F. Bogomolniy, R.R. Barakat, O. Lin, R. Soslow, E. Venkatraman, and J. Boyd Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma Gynecol. Oncol. 90 2003 378 381
187. M.N. Varras, G. Sourvinos, E. Diakomanolis, E. Koumantakis, G.A. Flouris, J. Lekka-Katsouli, S. Michalas, and D.A. Spandidos Detection and clinical correlations of ras gene mutations in human ovarian tumors Oncology 56 1999 89 96
188. M. Cuatrecasas, N. Erill, E. Musulen, I. Costa, X. Matias-Guiu, and J. Prat K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients Cancer 82 1998 1088 1095
189. M.K. Singh, K. Chetri, U.B. Pandey, V.K. Kapoor, B. Mittal, and G. Choudhuri Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer J. Gastroenterol. Hepatol. 19 2004 916 921
190. A. Rashid, T. Ueki, Y.T. Gao, P.S. Houlihan, C. Wallace, B.S. Wang, M.C. Shen, J. Deng, and A.W. Hsing K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China Clin. Cancer Res. 8 2002 3156 3163
191. S. Bezieau, M.C. Devilder, H. Avet-Loiseau, M.P. Mellerin, D. Puthier, E. Pennarun, M.J. Rapp, J.L. Harousseau, J.P. Moisan, and R. Bataille High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis Hum. Mutat. 18 2001 212 224
192. P. Liu, T. Leong, L. Quam, D. Billadeau, N.E. Kay, P. Greipp, R.A. Kyle, M.M. Oken, and B. Van Ness Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial Blood 88 1996 2699 2706
193. M. Ridanpaa, R.A. Lothe, A. Onfelt, S. Fossa, A.L. Borresen, and K. Husgafvel-Pursiainen K-ras oncogene codon 12 point mutations in testicular cancer Environ. Health Perspect. 101 Suppl. 3 1993 185 187
194. J.W. Moul, S.M. Theune, and E.H. Chang Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization Genes Chromosomes Cancer 5 1992 109 118